20 January 2026
20 January 2026
Despite lacklustre dealmaking, there were still trends identified from company presentations, such as pharma's upcoming patent cliff and AI's growth in medtech.
The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.
Despite a lacklustre FDI environment in British life sciences, the pharma industry could be set for a period of renaissance amid US trade agreements.
While GlobalData does not expect oral Wegovy to substantially displace sales of injectable versions in 2026, some sales cannibalisation in the medium-term outlook is inevitable.
The acquisition gives AstraZeneca full global control of the therapy’s development, manufacturing and commercialisation.
The RMAT designation is intended to expedite the development and evaluation of regenerative medicine therapies.
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans at the 44th Annual JP Morgan Healthcare Conference to start first‑in‑human trials of its IMC‑S118AI type 1 diabetes candidate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
